For stem cell and gene therapies, success presents a new challenge: mass production

Biotech companies in the scientific frontiers of stem cell and gene therapies are used to dealing with failures, loss of funding and other setbacks. Now they’re having to deal with new issues raised by success, according to experts speaking Monday in a panel at Biotech Showcase in San Francisco.

Click to view original post

Advertise With Us